As of Thursday close, Maravai LifeSciences Holdings Inc.’s (NASDAQ:MRVI) stock was up $0.11, moving up 0.92 percent to $12.06. The average number of shares traded per day over the past five days has been 3,569,940 shares. 4 times new highs have been achieved over the past 5 days, with a $0.63 gain in that time frame. In the last twenty days, the average volume was 2,321,225, while in the previous 50 days, it was 2,288,688.
Since last month, MRVI stock retreated -1.07%. Shares of the company fell to $10.78 on 08/02/23, the lowest level in the past month. A 52-week high of $27.82 was reached on 02/23/23 after having rallying from a 52-week low of $10.78. Since the beginning of this year, MRVI’s stock price has dropped by -15.72% or -$2.25, and marked a new high 7 times. However, the stock has declined by -56.65% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Right now, Maravai LifeSciences Holdings Inc. (MRVI) has a P/E ratio of about 6.05. The stock’s beta is -0.28. Besides these, the trailing price-to-sales (P/S) ratio of 4.21, the price-to-book (PB) ratio of 3.05.
Financial Health
In the three months ended March 30, Maravai LifeSciences Holdings Inc.’s quick ratio stood at 5.70, while its current ratio was 6.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 1.03, and the total debt-to-equity ratio was 1.04. On the profitability front, the trailing twelve-month gross margin is 77.30% percent. Based on annual data, MRVI earned $714.04 million in gross profit and brought in $883.0 million in revenue.
In Maravai LifeSciences Holdings Inc.’s quarter-end financial report for March 30, it reported total debt of $521.16 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. MRVI’s revenue fell -209.11% to $204.71 million during the quarter, while net income inched up to $79.03 million. While analysts expected Maravai LifeSciences Holdings Inc. to report $0.04 quarterly earnings, the actual figure was $0.03 per share, beating the consensus estimate by -25.00%. During the quarter, the company generated $14.16 million in EBITDA. The liabilities of Maravai LifeSciences Holdings Inc. were 1.41 billion at the end of its most recent quarter ended March 30, and its total debt was $603.8 million. The value of shareholders’ equity is $250.98 million.
Technical Picture
This quick technical analysis looks at Maravai LifeSciences Holdings Inc.’s (MRVI) price momentum. With a historical volatility rate of 58.67%, the RSI 9-day stood at 51.73% on 03 August.
With respect to its five-day moving average, the current Maravai LifeSciences Holdings Inc. price is up by +5.51% percent or $0.63. At present, MRVI shares trade -0.08% below its 20-day simple moving average and -17.74% percent below its 100-day simple moving average. However, the stock is currently trading approximately -11.32% below its SMA50 and -37.45% below its SMA200.
Stochastic coefficient K was 38.45% and Stochastic coefficient D was 23.66%, while ATR was 0.63. Given the Stochastic reading of 59.95% for the 14-day period, the RSI (14) reading has been calculated as 47.66%. As of today, the MACD Oscillator reading stands at -0.01, while the 14-day reading stands at -0.30.
Analyst Ratings
Maravai LifeSciences Holdings Inc. downgraded its rating on Maravai LifeSciences Holdings Inc. (NASDAQ: MRVI) to a Neutral in a note to investors on May 23, 2023. The analysts firm previously had an Outperform rating on the stock.Maravai LifeSciences Holdings Inc. (MRVI) has been rated Overweight by analysts. According to 0 brokerage firms, MRVI is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Maravai LifeSciences Holdings Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $18.00, the current consensus forecast for the stock is $12.00 – $27.00. Based on these forecasts, analysts predict Maravai LifeSciences Holdings Inc. (MRVI) will achieve an average price target of $18.58.
